BDC Capital, DSM Venturing lead Series B funding of Interface Biologics
Interface Biologics Inc has closed a Series B financing round. The value of the investment was not disclosed. The deal was led by DSM Venturing, the technology investment arm of Dutch health, nutrition and materials business Royal DSM, and BDC Capital Healthcare Venture Fund, an existing investor. Interface Biologics said it will use the proceeds to accelerate the commercialization of its biomedical polymer technologies platform, which is aimed at improving the safety and effectiveness of medical devices. Based in Toronto, the company was founded in 2001 as a spinoff of the University of Toronto. It is also backed by Covington Capital Corp and MaRS Investment Accelerator Fund.
13 January 2015•3 mins read
